Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer

Resistance to targeted drugs is now a challenging clinical problem in the treatment of non-small cell lung cancer (NSCLC). So far, there are no approved targeted therapeutic drugs for patients with disease progression after the third-generation epidermal growth factor receptor-tyrosine kinase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hang, Muhetaer, Gulizeba, Xie, Yizi, Yao, Kainan, Ma, Qianqian, Guan, Huiting, Xing, Sizhong, Huang, Xiufang, Zhou, Jihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719927/
https://www.ncbi.nlm.nih.gov/pubmed/36479196
http://dx.doi.org/10.3389/fphar.2022.1071365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719927/
https://www.ncbi.nlm.nih.gov/pubmed/36479196
http://dx.doi.org/10.3389/fphar.2022.1071365

Ejemplares similares